Intervention
lorlatinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentNCT07567352 · 2026-05-01
ACTIVE_NOT_RECRUITINGExplore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial TranscriptomicsNCT06893354 · 2025-05-10
NOT_YET_RECRUITINGLorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaNCT06858410 · 2025-03-01
NOT_YET_RECRUITINGA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETEDPF-07284892 in Participants With Advanced Solid TumorsNCT04800822 · 2021-03-17
TERMINATEDReal-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.NCT04647110 · 2020-12-14
COMPLETEDHepatic Impairment Study for Lorlatinib in Cancer PatientsNCT03726333 · 2020-01-14
TERMINATEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED2
NOT_YET_RECRUITING2
TERMINATED2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE12
PHASE31
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.